| 24.44 0.55 (2.3%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.04  |
1-year : | 33.92 |
| Resists | First : | 24.87 |
Second : | 29.04 |
| Pivot price | 23.65 |
|||
| Supports | First : | 21.32 |
Second : | 19.13 |
| MAs | MA(5) : | 23.76 |
MA(20) : | 23.2 |
| MA(100) : | 19.21 |
MA(250) : | 17.54 |
|
| MACD | MACD : | 1 |
Signal : | 1.1  |
| %K %D | K(14,3) : | 72.4 |
D(3) : | 68.6 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 25 | Low : | 8.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DYN ] has closed below upper band by 7.1%. Bollinger Bands are 52% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 24.9 - 25 | 25 - 25.1 |
| Low: | 23.46 - 23.56 | 23.56 - 23.67 |
| Close: | 24.26 - 24.44 | 24.44 - 24.6 |
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Fri, 24 Jul 2026
Dyne Therapeutics Grants New Hires Options on Up to 358,600 Shares - Stock Titan
Thu, 23 Jul 2026
Dyne Therapeutics Sells 21M Shares at $20.50 in Offering - Stock Titan
Thu, 23 Jul 2026
DYN: Dyne Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Thu, 23 Jul 2026
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Wed, 22 Jul 2026
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - Yahoo Finance
Wed, 22 Jul 2026
Dyne Therapeutics Stock Tumbles After Hours: Here's Why - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 165 (M) |
| Shares Float | 165 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 115.6 (%) |
| Shares Short | 22,300 (K) |
| Shares Short P.Month | 22,280 (K) |
| EPS | -3.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -58.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -442 (M) |
| Levered Free Cash Flow | -292 (M) |
| PE Ratio | -7.76 |
| PEG Ratio | 0 |
| Price to Book value | 4.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|